48 research outputs found
Gigliola Sulis speaks to Ann Goldstein: writing locally, translating globally
The conversation focuses on attitudes and trends in the US publishing market toward translated fiction. The strategies used by Goldstein as a translator of geo-centred and multilingual Italian novels are analysed, with reference to her translations of Pier Paolo Pasolini, Primo Levi, Elena Ferrante, Milena Agus, and Amara Lakhous
Augustinus-Lexikon. Ed. C. Mayer, 1, 1/2. Aaron-anima, animus. 1, 3. Anima, animus-Asinus. Basle and Stuttgart: Schwabe, 1986; 1988. Pp. li + 320, 1 col. pl., 1 folding map; pp. 321–480. ISBN 3-7965-0855-3; 3-7965-0867-7.
Rosario Pintaudi (ed.): Marsilio Ficino, Lessico greco-latino: Laur. Ashb. 1439. Pp. xxxi + 185. Rome: Edizioni dell'Ateneo e Bizzarri, 1977. L. 8,000.
Effects of adenosine derivatives on human and rabbit platelet aggregation. Correlation of adenosine receptor affinities and antiaggregatory activity
The inhibitory effects of several adenosine analogues, including the new A2-selective agonists 2-[p-(2-carboxyethyl)phenethylamino]-5'-N-ethylcarboxamido-adenosi ne (CGS 21680) and 2-hexynyl-5'-N-ethylcarbox-amidoadenosine (2-hexynyl-NECA), were investigated in vitro on human and rabbit platelet aggregation. The compounds examined inhibited ADP-induced platelet aggregation over a wide range of potency. The rank order of activity was similar between the two species thus showing that the rabbit is a useful animal model for studying the effects of adenosine derivatives on platelet aggregation. 2-Hexynyl-NECA was found to be the most potent adenosine compound of those currently available, having IC50 values of 0.10 and 0.07 microM in human and rabbit platelets, respectively. Conversely, the A1 agonists R(-)-N6-(2-phenylisopropyl) adenosine (R-PIA), S(+)-N6-(2-phenylisopropyl) adenosine (S-PIA) and 2-chloro-N6-cyclopentyladenosine (CCPA) were the least potent compounds with IC50 values in the micromolar range. The potency of the compounds in inhibiting platelet aggregation was found to be highly correlated with their affinity for A2 receptors as measured using 3H-CGS 21680 binding in rat brain striatum
Characterization of A2 adenosine receptor binding sites in human platelet using [3H] CGS 21680
Synthesis of the tritium labeled SCH 58261, a new non-xanthine A(2A) adenosine receptor antagonist
--
Binding of the adenosine A2A receptor ligand 3H CGS 21680 to human platelet membranes
A2A adenosine receptors were studied in human platelets through saturation and competition binding experiments
Binding characteristics of adenosine A2 receptor ligand 3H CGS 21680 to human platelet membranes
The binding characteristics of the selective adenosine A2 agonist [3H]CGS 21680 ([3H]2-[p-(2-carboxyethyl)-phenethyl-amino]-5'-N- ethylcarboxamidoadenosine) were determined in human platelet membranes. Specific binding was saturable, reversible and dependent upon protein concentration. Saturation experiments revealed a single class of binding sites with Kd and Bmax values of 1.4 microM and 5.9 pmol/mg of protein, respectively. Adenosine receptor agonists and antagonists competed for the binding of [3H]CGS 21680 (50 or 200 nM) to human platelet membranes showing a rank order of potency consistent with that typically found for interactions at the adenosine A2 receptor. Adenylate cyclase stimulation and platelet aggregation inhibition induced by adenosine agonists exhibited a rank order of potency close to that observed in binding experiments. However, the adenosine A1 receptor agonists, R- and S-N6-(2-phenylisopropyl)adenosine, (R-PIA) and (S-PIA), N6-cyclohexyladenosine (CHA) and 2-chloro-N6-cyclopentyladenosine (CCPA), which stimulate adenylate cyclase and inhibit platelet aggregation in the low microM range, displaced [3H]CGS 21680 only in the high microM range. In conclusion, we have found that [3H]CGS 21680, which is widely used as a specific A2 agonist in binding studies on brain tissues, is not appropriate for the characterization of the human platelet adenosine A2 receptor